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Abstract
Background: ETS transcription factors regulate important signaling pathways involved in cell differentiation and
development in many tissues and have emerged as important players in prostate cancer. However, the biological impact of
ETS factors in prostate tumorigenesis is still debated.
Methodology/Principal Findings: We performed an analysis of the ETS gene family using microarray data and real-time PCR
in normal and tumor tissues along with functional studies in normal and cancer cell lines to understand the impact in
prostate tumorigenesis and identify key targets of these transcription factors. We found frequent dysregulation of ETS genes
with oncogenic (i.e., ERG and ESE1) and tumor suppressor (i.e., ESE3) properties in prostate tumors compared to normal
prostate. Tumor subgroups (i.e., ERG
high, ESE1
high, ESE3
low and NoETS tumors) were identified on the basis of their ETS
expression status and showed distinct transcriptional and biological features. ERG
high and ESE3
low tumors had the most
robust gene signatures with both distinct and overlapping features. Integrating genomic data with functional studies in
multiple cell lines, we demonstrated that ERG and ESE3 controlled in opposite direction transcription of the Polycomb
Group protein EZH2, a key gene in development, differentiation, stem cell biology and tumorigenesis. We further
demonstrated that the prostate-specific tumor suppressor gene Nkx3.1 was controlled by ERG and ESE3 both directly and
through induction of EZH2.
Conclusions/Significance: These findings provide new insights into the role of the ETS transcriptional network in prostate
tumorigenesis and uncover previously unrecognized links between aberrant expression of ETS factors, deregulation of
epigenetic effectors and silencing of tumor suppressor genes. The link between aberrant ETS activity and epigenetic gene
silencing may be relevant for the clinical management of prostate cancer and design of new therapeutic strategies.
Citation: Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, et al. (2010) ETS Transcription Factors Control Transcription of EZH2 and Epigenetic
Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer. PLoS ONE 5(5): e10547. doi:10.1371/journal.pone.0010547
Editor: Chad Creighton, Baylor College of Medicine, United States of America
Received November 3, 2009; Accepted April 12, 2010; Published May 10, 2010
Copyright:  2010 Kunderfranco et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from Oncosuisse (OCS-01913-08), Swiss National Science Foundation (FNS-31003A-118113) and Ticino Foundation
for Cancer Research to GMC. MGM and CG were supported by Compagnia di San Paolo, Torino, Italy. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pina.carbone@irb.unisi.ch
Introduction
Cancer of the prostate is the most common cancer and a leading
cause of cancer death in western countries [1]. Prostate cancer has
a highly heterogeneous clinical behavior and little is known about
the molecular mechanisms contributing to this heterogeneity [1].
Recently, ETS transcription factors have emerged as important
elements in prostate tumorigenesis due to the finding of recurrent
translocations involving ETS genes, the most frequent being the
TMPRSS2: ERGa gene fusion leading to over-expression of full
length ERG [2,3,4]. However, the biological impact of translo-
cated ETS genes is still debated. Recent reports suggest that ERG
over-expression is not sufficient to induce neoplastic transforma-
tion and cooperation with other oncogenic pathways, such as
PTEN loss and PI3K/AKT dysregulation, is necessary [5,6,7,8,9].
The human ETS family includes 27 members that share a highly
conserved DNA binding domain and are nodal points of various
signaling pathways controlling cell proliferation, differentiation
and survival [10]. Although there is great potential for overlap,
individual ETS factors have distinct features that manifest through
positive and negative regulation of different subsets of genes and
biological processes [10]. Moreover, in many tissues ETS factors
constitute complex regulatory networks with specific cellular
responses depending on the balance between factors with similar
or opposite functions [10]. Most ETS factors, like those
translocated in prostate cancer, promote cell proliferation, survival
and transformation, while others act as tumor suppressors [10].
Recently, we found that the epithelial-specific ETS factor ESE3
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affected cell proliferation and survival, and acted as tumor
suppressor in prostate epithelial cells [11]. Thus, to understand
the overall impact of ETS gene deregulation in tumorigenesis and
identify key targets of deregulated ETS factors, it would be
important to consider the entire set of ETS genes expressed in a
given tissue.
In this study, through a comprehensive analysis of the ETS gene
family in prostatic normal and tumor tissues, we identified tumor
subgroups with distinct ETS expression patterns. Besides already
known ETS targets, we discovered previously unrecognized genes
and pathways linked to aberrant ETS activity. By integrating
genomic data with functional studies, we established that the
Polycomb Group (PcG) protein EZH2 is a direct target of ERG
and ESE3, and a key player in transcriptional silencing of the
prostate specific tumor suppressor gene Nkx3.1. Taken together,
our data reveal more frequent and complex alterations of ETS
genes than previously recognized and identify key genes like EZH2
and Nkx3.1 contributing to the reprogramming of prostate
epithelial cell transcriptome in response to aberrant expression
of oncogenic and tumor suppressor ETS factors. These findings
may be relevant for the clinical management for prostate cancer
and design of new therapeutic strategies.
Results
ETS Gene Expression Patterns Define Prostate Cancer
Subgroups
To gain a comprehensive view of the ETS transcriptional
network in prostate cancer, we examined the expression of the
ETS gene family in microarray datasets from primary prostate
cancer (n=59) and normal prostate (n=14) clinical samples.
Analysis of microarray data showed that several ETS genes were
differentially expressed in tumor samples compared to normal
prostate. Quantitative RT-PCR (QRT-PCR) was used to confirm
the differential expression of the most frequently altered ETS
factors (Fig. S1). The most significantly affected ETS genes were
ERG, ESE3 and the epithelial-specific ETS factor-1 (ESE1/
ELF3/ESX). We previously showed that ESE3, that is expressed
in normal prostate epithelial cells, negatively affected proliferation
and survival of prostate cancer cells and proposed that it acted as a
tumor suppressor [11]. ESE1, which is closely related to ESE3, is
expressed in normal epithelial cells of various organs, including
prostate, breast and lung and is known to act as an oncogene when
over-expressed in breast epithelial cells [12,13]. However, up-
regulation of ESE1 in prostate tumors has not been reported
before. Overall, dysregulated expression of ETS genes was very
frequent in prostate tumors. Indeed, most of the tumors had at
least one up- or down- regulated ETS gene compared to normal
prostate and often multiple ETS were simultaneously affected.
Our objective was to understand how these individual and
compounded ETS alterations could affect the biology of prostate
cancer. Using QRT-PCR data on ETS gene expression and
genomic data we evaluated whether specific transcriptional
profiles were associated with the distinct ETS expression patterns.
We used several criteria to minimize the potential confounding
effects of the presence of multiple ETS factors. First, QRT-PCR
data were used to classify accurately tumors according to their
ETS gene expression status. Then, only tumors with very high or
very low expression of a given ETS (i.e., $4-fold higher or lower
than the average value in normal prostate) were assigned to a
group and included in the analysis. Using these criteria
approximately 80% of prostate cancers had highly deregulated
expression of at least one predominant ETS gene. On these bases,
we identified three major tumor subgroups characterized by the
predominant dysregulation of an ETS factor: i) tumors with high
ERG expression (ERG
high, n=14), ii) tumors with high ESE-1
expression (ESE1
high, n=12) and iii) tumors with low ESE3
expression (ESE3
low, n=13). A fourth group (NoETS, n=14)
included tumors that had normal-like levels of all ETS gene
(Fig. 1A). Eight tumors with $4-fold over-expression either of
ETV1, ETV4, ETS2 or ETS1 were excluded from the analysis
because of their limited numbers. ESE1 was highly expressed in 26
of the 59 (44%) prostate tumors, but only in 12, which were
included in the ESE1
high expressing group, it was the only over-
expressed ETS. ESE3 was down-regulated $4 fold in 27 of the 59
(46%) prostate tumors but only in the 13 cases, which were
included in the ESE3
low expressing group, it was the only
deregulated ETS. We applied a similar approach to a publicly
available microarray dataset from an independent study [14]
obtaining a similar distribution of prostate tumors in four major
subgroups (Fig. S2). Interestingly, in our series 6 and 8 of the 14
ERG
high tumors had concomitantly dysregulated expression of
ESE3 and ESE1, respectively (Fig. 1A). Similarly in the public
dataset the 15 ERG
high tumors had concomitantly dysregulated
expression of ESE3 and ESE1 (Fig. S2A). Thus, ERG over-
expression could clearly coexist with dysregulated expression of
these other ETS factors. In our tumor series, 11 of the 14 ERG
high
tumors (79%) were positive for the TMPRSS2: ERGa fusion
transcript assessed by end-point RT-PCR (Fig. S3A). The other
ERG over-expressing tumors had likely other types of fusion
transcripts not detected by the assay. Seven tumors had very low
levels of TMPRSS2: ERGa transcript by end-point RT-PCR,
normal-like expression of ERG by QRT-PCR and were not
included in the ERG
high group. None of the 8 normal samples and
of the 11 benign prostatic hyperplasia (BPH) samples examined
had evidence of the TMPRSS2: ERGa transcript (Fig. S3A).
Clinical and pathological parameters of the four tumor subgroups
are shown in Fig. S3B. There was no statistically significant
association between ETS subgroups and any of the assessed
clinical/pathological parameters.
Transcriptional Programs in Prostate Cancer Subgroups
We used Principal Component Analysis (PCA) to assess the global
degree of similarity or divergence of the individual transcriptomes of
normal and prostate cancer samples. As shown in Fig. 1B, tumors
belonging to different subgroups formed partially distinct clusters
suggesting that divergence in the transcriptional programs depended
at least in part on their ETS gene expression patterns. ERG
high and
ESE3
low tumors were the most distant from normal prostate and
largely distinct from the other subgroups. Next, we compared the
transcriptional profiles of the tumor subgroups with that of normal
prostate using Gene Expression Profile Analysis Suite (GEPAS) [15]
to identify common and distinct features and extract ETS-specific
gene signatures. The number of differentially expressed genes
(Q#0.1) in each subgroup is shown in Fig. 1C and the gene lists
a r es h o w ni nT a b l eS 1 .E R G
high and ESE3
low tumors had the most
robust gene signatures with the largest number of differentially
expressed genes relative to normal prostate, while the number of
differentially expressed genes was considerably less in ESE1
high and
NoETS tumors.
Next, we crossed the lists of differentially expressed genes
relative to normal prostate to determine the degree of overlap and
divergence among tumor subgroups (Fig. 1D-E). Notably,
ERG
high and ESE3
low tumors shared many differentially expressed
genes with a large overlap among both up-regulated and down-
regulated genes, indicating that altered expression of ERG and
ESE3 had partially similar effects. On the other hand, ERG
high
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low tumors had a large number of distinctive features
relative to No ETS (Fig. 1D) and ESE1
high (Fig. 1E) tumors. These
differences in gene set overlap were statistically significant
(P,0.0001, Fisher Exact test). The genes modulated both in
ERG
high and ESE3
low tumors but not in the other tumor
subgroups, identified through a 3-way (Fig. 1D) and 4-way (Fig.
S4) Venn diagrams, are listed in Table S2.
To understand the functional implications of the differences
among the tumor subgroups we used Metacore, a software suite
for integrated functional analysis of the gene expression data [16].
Figure 1. ETS gene signatures in prostate cancer. A. Expression of ERG, ESE1 and ESE3 determined by qRT-PCR in normal prostate and prostate
tumors. Tumors are grouped according to the predominantly expressed ETS factor. B. Principal component analysis. Dots represent individual
samples with their location determined by the principal components of the transcriptome. C. Number of differentially expressed genes with Q#0.1 in
each ETS subgroup. D-E. Venn diagrams showing shared and distinct differentially expressed genes among the indicated tumor subgroups.
doi:10.1371/journal.pone.0010547.g001
ETS Factors and Epigenetic
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10547Metacore allowed to map common, similar and unique features
among tumor subgroups and define commonly and differentially
affected Gene Ontology pathways. As shown in Fig. 2A, there
were many common and similar features among the tumor
subgroups. On the other hand, ERG
high and ESE3
low tumors had
the largest number of unique features. The top commonly affected
GeneGo pathway maps (GGPM), shown in Fig. 2B, included
immune response, cytoskeleton remodeling, development, cell cycle and
transcriptional regulation. They may represent genes and pathways
commonly activated in tumors compared to normal tissue. The
differentially affected GGPMs were prevalently or exclusively
enriched in ERG
high and ESE3
low tumors (Fig. 2C). The top
differentially affected GGMPs included cell adhesion-integrin mediated,
cytoskeleton remodeling, cell adhesion-ECM remodeling and cell adhesion-
chemokines, suggesting that activation of these pathways, related to
cell migration and invasion, could be predominant features of
these tumors. Interestingly, these data implicated also that ESE3
loss had consequences quite similar to ERG over-expression on the
transcriptional program of prostate tumors.
ERG Upregulates EZH2 Expression in Prostate Tumors
Comprehensive evaluation of ETS gene expression and genomic
data showed robust and partially overlapping gene signatures in the
ERG
high and ESE3
low tumors with many activated and repressed
genes. Next, we searched ERG
high and ESE3
low signatures for target
genes that could act as key nodes mediating the effects of these
aberrantly expressed ETS factors on the prostate cancer transcrip-
tome. EZH2 was among the 169 up-regulated genes both in ERG
high
and ESE3
low tumors genes (Fig. S4 and Table S2) while it was not
increased in the other tumor subgroups. EZH2 was also positively
correlated with ERG and negatively correlated with ESE3 in a
correlation analysis of the entire microarray dataset (Table S3).
EZH2 isa histone H3lysine 27 (H3K27) methyltransferaseand a key
element in epigenetic gene silencing [17,18]. H3K27 methylation is a
histone mark that creates an anchoring point for the recruitment of
additional chromatin remodeling factors inducing a repressive
chromatin state [17]. Thus, the induction of EZH2 associated with
ERG gain and ESE3 loss could contribute to the broad repressive
signature observed in these tumors (Fig. 1C). EZH2 has been shown
Figure 2. Functional analysis of the transcriptional programs of prostate tumor subgroups. A. Number of unique, similar and common
features among the differentially expressed genes compared to normal prostate in ERG
high, ESE3
low, ESE1
high and NoETS tumors according to
Metacore. B. Commonly affected GeneGo Pathway Maps in the tumor subgroups. C. Differentially affected GeneGo Pathway Maps in ERG
high,
ESE3
low, ESE1
high and NoETS tumors.
doi:10.1371/journal.pone.0010547.g002
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with particularly higher levels in high grade and metastatic tumors
[19]. However, few factors have been identified that might increase
EZH2 expression in prostate tumors [20,21,22,23]. We found that
EZH2 wassignificantlyup-regulated inERG
hightumors compared to
both normal prostate and NoETS tumors (Fig. 3A), indicating that
there might be a direct link between EZH2 and ERG expression that
had not been recognized before. Consistent with this finding, EZH2
was significantly higher in ERG
high compared to NoETS tumors
(Q,0.0001) also in an independent dataset (Fig. 3B).
Next, we probed the functional relationship between ERG
and EZH2 and the possibility of direct regulation of EZH2 by
Figure 3. ERG induces EZH2 expression. A. EZH2 expression in tissue samples. Microarray data are presented as log2 ratios compared to the
reference. B. EZH2 expression in NoETS and ERG
high tumors in the Wallace et al. microarray dataset. C. EZH2 expression in LNCaP and 22Rv1 cells
transiently transfected with empty (ev) or ERG expression (Erg) vector determined by RT-PCR (left) and Western blot (right). D. EZH2 level in control
and stable ERG-expressing 22Rv1 and LNCaP cells determined by RT-PCR (upper) and Western blot (bottom). E. EZH2 level in VCaP cells transiently
transfected with control and ERG-specific (siERG) siRNA determined by RT-PCR (left) and Western blot (right). F. ChIP in the indicated cell lines with
ERG antibody and qPCR with primer sets encompassing the EBS in the EZH2 promoter. Positive (MMP3 promoter) and negative (ETS2) controls are
shown in Fig. S6A-B and 7A, respectively. G Tissue specimens of ERG
high and NoETS tumors were subjected to ChIP with anti-ERG antibody and
analyzed by qPCR. ETS2 was used as negative control (Fig. S7B). *, P,0.01; **, P,0.0001.
doi:10.1371/journal.pone.0010547.g003
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and down-regulated ERG. In these experiments we over-
expressed ERG in ERG-translocation negative 22Rv1 and
LNCaP prostate cancer cells that do not express endogenous
ERG. Upon transfection, 22Rv1 and LNCaP cells expressed
ERG to levels similar to TMPRSS2: ERG translocation positive
VCaP cells (Fig. S5A). In parallel, knock-down of ERG was
performed in VCaP cells using an ERG specific siRNA. The
level of ERG RNA and protein was significantly reduced in
siRNA transfected cells compared to control VCaP cells (Fig.
S5B). To validate these cellular models, we examined the
expression of genes, like MMP3, PLA-1 and CRISP3, which
were at the top of the list of up-regulated genes in ERG
high
tumors and had been previously shown to be controlled by ERG
in other cell systems [6]. Expression of these genes increased
upon ERG over-expression in 22Rv1 and LNCaP cells (Fig.
S5C) and decreased upon ERG knock-down in VCaP cells (Fig.
S5D). These results demonstrated the adequacy of our cellular
models to investigate potential ERG target genes along with the
predictive value of the gene signatures that we derived from
prostate cancer clinical samples.
Both transient and stable expression of ERG in ERG-negative
LNCaP and 22Rv1 cells led to increased level of EZH2 (Fig. 3C-
D). Furthermore, EZH2 mRNA and protein were reduced upon
siRNA-mediated knock-down of ERG in VCaP cells (Fig. 3E).
The changes in EZH2 expression observed upon up- and down-
regulation of ERG suggested the possibility of direct regulation by
ERG. We identified putative ETS binding sites (EBSs) within 1 kb
of the EZH2 TSS by computational analysis and performed ChIP
experiments to determine whether ERG was able to bind to these
sites (Fig. 3F). Binding of ERG to the EZH2 promoter was
observed in ERG translocation positive VCaP cells and in LNCaP
and 22Rv1 cells upon stable expression of ERG, while no binding
was seen in non-ERG expressing parental LNCaP and 22Rv1 cells
(Fig. 3F). Similarly, ERG was bound to the MMP3 gene, a known
ERG target used here as positive control, only in ERG expressing
clones and in VCaP cells (Fig. S6A). No binding of ERG was seen
to the ETS2 promoter, which was used as a negative control (Fig.
S7A). The region of the ETS2 promoter assessed by ChIP
included the transcription start site and both RNA polymerase II
and Sp1 had been shown to bind to this region in gel shift and
ChIP assays ([24] and data not shown). Taken together, these data
supported the conclusion that ERG acted as a transcriptional
activator of EZH2 by binding to its promoter. Finally, to prove
that this interaction occurred also in clinical tumor specimens we
performed ChIP to assess binding of ERG to the EZH2 promoter
in ERG
high and NoETS samples (Fig. 3G). ERG was associated to
the EZH2 promoter in ERG
high tumors while it was absent in
NoETS tumors, consistent with the hypothesis that it controlled
transcription of this gene. Specificity was demonstrated by the
absence of binding of ERG to the ETS2 promoter in the tumor
samples (Fig. S7B).
ERG Represses Nkx3.1 in Prostate Tumors through EZH2
and Histone H3K27 Methylation
In addition to up-regulated genes, the transcriptome of ERG
high
tumors included numerous genes whose expression was significantly
reduced compared to normal prostate, suggesting that these genes
might be repressed either directly or indirectly by ERG. The list of
down-regulated genes in ERG
high tumors included many relevant
genes that could have significant impact on the prostate cancer
biology. Among genes with known tumor suppressor functions, we
focused on Nkx3.1, which was similarly affected in ERG
high and
ESE3
low tumors. Nkx3.1 is a prostate-specific homeobox gene and a
transcription factor that has critical functions in prostate development
and tumor suppression [25]. Loss of Nkx3.1 expression is a frequent
event in prostate tumorigenesis and has been attributed to various
mechanisms including allelic loss, methylation and post-transcrip-
tional silencing [25,26,27,28]. We found that the level of Nkx3.1 was
significantly reduced in ERG
high tumors compared to normal
prostate and NoETS tumors (Fig. 4A). To determine whether
Nkx3.1 down-regulation was functionally linked to ERG over-
expression, we examined the level of Nkx3.1 in prostate cancer cells
upon modulation of ERG. ERG knock-down in VCaP cells resulted
in increased Nkx3.1 expression at the mRNA and protein level
(Fig. 4B). On the other hand, Nkx3.1 level was reduced by stable
expression of ERG in ERG negative LNCaP and 22RV1 cells,
providing further evidence of control of Nkx3.1 expression by ERG
(Fig. 4B). Since ETS factors can act as transcriptional activators or
repressors depending on the promoter context [10,29], we searched
the Nkx3.1 promoter for possible EBS that could mediated ERG
binding. Computational analysis showed the presence of a putative
EBS in the Nkx3.1 promoter. ChIP assays showed binding of ERG to
this region of the promoter in VCaP cells (Fig. 4C). ERG occupied
the Nkx3.1 promoter also in LNCaP and 22Rv1 cells upon stable
ERG expression and concomitantly to the silencing of the gene
(Fig. 4C). Thus, binding of ERG to the Nkx3.1 promoter was
associated with transcriptional repression of the gene. We observed
Nkx3.1 promoter occupancy by ERG also in clinical tumor samples
by performing ChIP in ERG
high and NoETS tumors. ERG was
bound to the Nkx3.1 promoter in ERG
high tumors, consistent with
the hypothesis that it controlled negativelytranscription of the gene in
this tumor subgroup (Fig. 4D).
To determine whether the induction of EZH2 by ERG could
contribute to the silencing of Nkx3.1, we knocked-down EZH2 in
ERG expressing cells. siRNA-mediated knock-down of EZH2 in
VCaP cells increased expression of Nkx3.1, consistent with the
hypothesis that the gene was under the control of EZH2 in these
cells (Fig. 4E). Furthermore, EZH2 knock-down in ERG
expressing LNCaP clones partially restored Nkx3.1 expression
to a level similar to that of parental LNCaP cells (Fig. 4E). To
further prove the role of EZH2, we determined by ChIP whether
the Nkx3.1 promoter acquired the H3K27 methylation mark
characteristic of EZH2 activity in cells in which the gene was
repressed. We observed increased H3K27 methylation in the
region surrounding the EBS, which we indentified in the
promoter, and at the level of an androgen responsive enhancer
(ARE), which is an important regulatory site in the Nkx3.1 gene
[30] in ERG-translocation positive VCaP cells (Fig. 4F). A similar
enrichment of H3K27 methylation was also observed in LNCaP
and 22Rv1 cells with stable expression of ERG (Fig. 4F). Thus,
Nkx3.1 acquired a repressive mark characteristic of EZH2
activity in an ERG-dependent manner. Taken together, these
data established that Nkx3.1 was a target of both ERG and
EZH2. ERG repressed Nkx3.1 directly by binding to its promoter
and indirectly via the induction of EZH2 and H3K27
methylation. Luciferase reporter assays and transient transfection
experiments supported this hypothesis. Nkx3.1 promoter activity
and protein level were reduced upon transient expression of ERG
in LNCaP cells (Fig. 4G-H). In contrast, transient transfection of
EZH2 alone had no effect on Nkx3.1 promoter activity in
reporter assay or Nkx3.1 protein level (Fig. 4G-H), indicating that
EZH2 required ERG and stable expression to silence Nkx3.1.
These findings are thus consistent with the ability of ETS factors
to act alternatively as transcriptional activator and repressor
[10,29] and with the hypothesis that transcription factors can
influence the recruitment of epigenetic effectors like EZH2 to
gene promoters [31].
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PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10547Figure 4. ERG represses Nkx3.1 expression. A. Nkx3.1 expression in normal and tumor tissue samples. B. Nkx3.1 level in LNCaP cells transiently
transfected with empty (ev) or ERG expression (Erg) vector determined by Western blot (upper panel), Nkx3.1 level in VCaP cells transiently
transfected with siERG and control siRNA determined by RT-PCR and Western blot (middle panel), Nkx3.1 level in control and stable ERG-expressing
22Rv1 and LNCaP cells analyzed by RT-PCR and Western blot (bottom panel). C. Binding of ERG to the Nkx3.1 promoter determined by ChIP and
qPCR in indicated cell lines. Negative controls are shown in Fig. S7A. D. Tissue specimens of ERG
high and NoETS tumor were subjected to ChIP with
anti-ERG antibody and analyzed by qPCR. Negative controls are shown in Fig. S7B. E. VCaP, parental (control) and ERG expressing (ERG 18) LNCaP
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tion, is only one of multiple mechanisms contributing to silencing
of tumor suppressor genes in cancer cells [18]. The promoter of
Nkx3.1 gene contains a CpG island and the gene has been
reported to be silenced by CpG promoter methylation in prostate
tumors [26]. Thus, we determined whether DNA methylation was
also involved in ERG induced Nkx3.1 silencing. Bisulfite
sequencing showed the absence of CpG methylation in the
Nkx3.1 promoter in ERG-translocation positive VCaP cells and
ERG expressing and non-expressing LNCaP cells (Fig. 4I). In
contrast, the Nkx3.1 promoter was methylated in ERG-translo-
cation negative PC3 prostate cancer cells that do not express
Nkx3.1 (Fig. 4I) indicating that in these cells Nkx3.1 was silenced
by CpG promoter methylation. Thus, ERG-induced Nkx3.1
silencing relied mainly on EZH2 and was independent of
promoter methylation, consistent with reactivation of Nkx3.1
expression upon EZH2 knock-down.
ESE-3 Represses EZH2 and Activates Nkx3.1 Transcription
The transcriptome of ERG
high and ESE3
low tumors shared
many genes in common. This suggested that ERG and ESE3
could affect transcription of many genes in opposite directions and
that ERG up-regulation and ESE3 down-regulation could results
in partially similar effects on the prostate cancer transcriptome. As
seen in ERG
high tumors, EZH2 was significantly higher in
ESE3
low tumors compared to normal prostate and NoETS tumors
(Fig. 5A). The inverse relationship between ESE3 and EZH2
expression level was also seen in an independent microarray
dataset (Q,0.0004) [14] (Fig. 5B; S2D). These observations
suggested that ESE3 could negatively regulate EZH2 in the
prostate and loss of ESE3 could result in increased EZH2
expression in prostate tumors. To test this hypothesis, we
generated clones of LNCaP cells (ESE3-kd) in which we stably
knocked-down ESE3 using shRNA constructs. These clones had
significantly lower levels of ESE3 compared to parental LNCaP
cells, which express detectable levels of ESE3 (Fig. S5E).
Consistent with our hypothesis, ESE3-kd LNCaP cells had higher
expression of EZH2 than parental cells (Fig. 5C). To determine
whether ESE3 controlled the expression of EZH2 also in normal
prostate epithelial cells we stably knock-down ESE3 in immortal-
ized LHS cells [32], which we have shown previously to express
ESE3 [11]. shRNA-mediated knock-down was effective in
reducing ESE3 level in LHS cells (Fig. S5E, right panel) and,
consistent with our hypothesis, ESE3-kd LHS cells had a higher
level of EZH2 than parental cells (Fig. 5D). Thus, experimentally
reducing the level of ESE3 led to increased expression of EZH2,
suggesting that ESE3 maintains EZH2 repressed in prostate
epithelial cells.
Analysis of ESE3
low gene signature showed that, similar to
ERG
high tumors, ESE3
low tumors had also lower levels of Nkx3.1
compared to normal prostate and NoETS tumors (Fig. 5E). Thus,
ESE3 could control positively Nkx3.1. Consistently, we found that
the level of Nkx3.1 was reduced upon ESE3 knock-down in
LNCaP and LHS cells (Fig. 5F). Luciferase reporter assay showed
that ESE3 increased Nkx3.1 promoter activity when transfected in
ESE3 negative PC3 cells. On the other hand, ERG reduced
luciferase activity confirming the opposing effects of these ETS
factors on the Nkx3.1 promoter (Fig. 5G).
To determine whether the induction of EZH2 consequent to the
loss of ESE3 would lead also to Nkx3.1 repression in ESE3-kd
LNCaP cells, we knocked-down EZH2 in these cells. Down-
regulation of EZH2 in ESE3-kd LNCaP cells restored the
expression of Nkx3.1 to a level similar to parental cells (Fig. 6B).
Furthermore, the Nkx3.1 promoter acquired H3K27 methylation
in ESE3-kd cells (Fig. 6C), confirming that silencing of the gene was
also mediated by EZH2. To determine whether CpG promoter
methylation was involved in the silencing of Nkx3.1, we analyzed
the CpG methylation state in the Nkx3.1 promoter in ESE3-kd
LNCaP cells. Bisulfite sequencing showed the absence of CpG
methylation in the Nkx3.1 promoter in both parental and ESE3-kd
LNCaP cells (Fig. 4I) ruling out DNA methylation as a
contributing factor.
The changes observed in EZH2 and Nkx3.1 expression in
ESE3-kd cells suggested that ESE3 could bind to the promoter of
these genes and act alternatively as a transcriptional activator or
repressor. To test this hypothesis, we performed ChIP to assess
binding of ESE3 to the regions of the EZH2 and Nkx3.1
promoters containing the identified EBS in parental and ESE3-kd
LNCaP cells. As shown in Fig. 6C (right panel), binding of ESE3 to
the Nkx3.1 promoter was seen in parental and not in ESE3-kd
LNCaP cells, supporting the idea that ESE3 acted as a
transcriptional activator of this gene. ChIP showed also that
ESE3 was bound to the EZH2 promoter in parental LNCaP cells,
while binding was decreased in ESE-kd cells. In this case, binding
of ESE3 would have a negative effect on EZH2 transcription
(Fig. 6C, left panel).
These data indicated that ERG and ESE3 could bind to
overlapping sites in the EZH2 and Nkx3.1 promoters and regulate
their transcription in opposite directions. Thus, ERG and ESE3
might compete with each other for promoter occupancy, switching
alternatively on and off transcription. To test this hypothesis, we
performed ChIP to assess binding of ESE3 to the promoters in
parental and ERG-expressing LNCaP cells. ESE3 was bound to
the EZH2 promoter in parental cells, but its presence was
significantly reduced in ERG expressing cells, indicating that ERG
could displace ESE3 from the EZH2 promoter (Fig. 6D, left panel).
Consistently, ChIP showed also that binding of ESE3 to the
Nkx3.1 promoter was reduced in ERG over-expressing compared
to parental LNCaP cells (Fig. 6D, right panel). Thus, ERG and
ESE3 competed with each other for binding to these promoters.
ESE3 mediated activation of Nkx3.1 and repression of EZH2
could be reversed by ERG when over-expressed in prostate cells
by direct competition for promoter occupancy. Altogether, these
data support the existence of an ETS transcriptional network that
controls expression of key target genes involved in cell proliferation
and differentiation.
Aberrant Expression of ERG and ESE3 Increases Cell
Migration and Anoikis
Functional annotation analysis of the transcriptome of ERG
high
and ESE3
low tumors linked both ERG and ESE3 to critical
processes in tumor initiation and progression and suggested that
cells transfected with EZH2 specific (siEZH2) and control siRNA and analyzed by RT-PCR.F .ChIP with an antibody for methylated H3K27 and qPCR
with primer sets encompassing the EBS (upper panel) and an androgen responsive enhancer (ARE) (bottom panel) in the Nkx3.1 gene. ETS2 was used
as negative control (Fig. S8A). G. Nkx3.1 promoter activity in LNCaP cells transfected with human Nkx3.1 promoter reporter along with the indicated
expression vectors. Luciferase reporter activity was measured after 24 h. H. Nkx3.1 protein level in LNCaP cells transiently transfected with empty (2)
or either ERG (pERG) or EZH2 (pEZH2) expression vector determined by Western blot. I. Nkx3.1 promoter methylation was assessed by bisulfite-
treated DNA sequencing. Empty and filled circles represent unmethylated and methylated CpG sites, respectively. *, p,0.01; **, p,0.001.
doi:10.1371/journal.pone.0010547.g004
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understand the functional consequences of altered expression of
ERG and ESE3, we evaluated the effects of ERG over-expression
and ESE3 knock-down on cell migration using the in vitro scratch/
wound healing assay and on cell survival in non-adherent
conditions (anoikis assay). Resistance to anoikis, along with
increased cell motility, contributes to cancer cell dissemination
and metastasis. ERG expression increased cell migration of
LNCaP cells that have limited motility (Fig. 7A). LNCaP cells
with ESE3 knock-down exhibited also increased cell migration
compared to parental LNCaP cells (Fig. 7B). Resistance to anoikis
was increased both in ERG over-expressing and ESE3 knock-
down LNCaP cells (Fig. 7C-D). These findings support the
hypothesis that dysregulated expression of ERG and ESE3
induced similar phenotypes in prostate epithelial cells.
Transient knock-down of ERG in VCaP cells decreased survival
in anoikis conditions (Fig. 7E). To assess the contribution of EZH2
induction to this cell phenotype, we transiently knock-down EZH2
in VCaP (Fig. 7E) and parental and ERG-expressing LNCaP cells
(Fig. 7F). EZH2 knock-down significantly reduced resistance to
Figure 5. ESE-3 regulates EZH2 and Nkx3.1 expression. A. EZH2 level in normal prostate, ESE3
low and NoETS tumors. B. EZH2 level in NoETS
and ESE3
low tumors in Wallace et al. microarray dataset. C. EZH2 level in control (sh-) and stable ESE3 knock-down (sh 4, 6, 7) LNCaP clones
determined by RT-PCR. D. EZH2 level in control (sh-) and ESE3 knock-down (sh17, 28) LHS clones determined by RT-PCR. E. Nkx3.1 level in normal
prostate, ESE3
low and NoETS tumors. F. Nkx3.1 level in control (sh-) and ESE3-knock-down LNCaP and LHS cells determined by RT-PCR and Western
blot (right bottom). G. Nkx3.1 promoter activity in PC3 cells transfected with human NKx3.1 promoter reporter along with the indicated expression
vectors. Luciferase reporter activity was measured after 24 h. *p,0.01; **, p,0.001.
doi:10.1371/journal.pone.0010547.g005
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parental LNCaP cells (Fig. 7E-F), indicating that EZH2 mediated
at least in part the effects of aberrantly expressed ERG. To assess
also the contribution of Nkx3.1 to this malignant phenotype, we
transiently expressed Nkx3.1 in parental and ERG-expressing
LNCaP cells (Fig. 7G). Transient expression of Nkx3.1 signifi-
Figure 6. Silencing of Nkx3.1 is mediated by EZH2 in ESE3 knock-down cells. A. RNA was extracted from control (sh-) and ESE3 knock-
down (sh7) LNCaP cells 48 h post-transfection with siEZH2 and control siRNA and analyzed by RT-PCR. B. H3K27 methylation was assessed in sh- and
sh7 LNCaP cells by ChIP and qPCR with primers encompassing the EBS and ARE in the Nkx3.1 gene. ETS2 was used as negative control (Fig. S8B) C.
ESE3 binding to the EZH2 and Nkx3.1 promoter was assessed by ChIP and qPCR in sh- and sh7 LNCaP cells. ETS2 was used as negative control (Fig.
S9A). D. ESE3 binding to the EZH2 and Nkx3.1 promoter in control and ERG-expressing (ERG-18) LNCaP cells assessed by ChIP and qPCR. ETS2 was
used as negative control (Fig. S9B). *, p,0.01.
doi:10.1371/journal.pone.0010547.g006
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LNCaP cells without any effect in parental LNCaP cells, which
endogenously express Nkx3.1. A similar result was obtained by
transient expression of Nkx3.1 in ESE3 knock-down LNCaP cells
with a significant reduction of their ability to survive in anoikis
condition (Fig. 7H). Collectively, these data indicated that both
EZH2 and NKx3.1 mediated relevant effects of ERG and ESE3 in
prostate cancer cells.
Discussion
ETS transcription factors regulate important signaling pathways
involved in cell differentiation and development in many tissues
and have emerged as important players in pathogenesis of
epithelial and non-epithelial tumors [10]. ETS factors have
recently attracted significant attention in prostate cancer since
the identification of recurrent ETS gene rearrangements leading to
their over-expression [2,3,4]. This study provides new insights into
the relevance of the ETS transcriptional network in the prostate
and identifies a link between ETS factors, epigenetic pathways and
expression of tissue-specific differentiation and tumor suppressor
genes.
We found that dysregulated expression of ETS factors with
putative oncogenic and tumor suppressor properties was very
frequent, with up to 80% of prostate tumors having one or more
aberrantly expressed ETS gene. Thus, our study indicates that
prostate tumors truly without altered ETS gene expression
(NoETS) represent a relatively minor group. This is a relevant
finding made possible by the QRT-PCR assessment of the
expression level of multiple ETS genes in cancer and normal
prostate tissue samples, which to our knowledge had not been
evaluated before. Most tumors, which would have been classified
as ETS negative based on the exclusive assessment of the few ETS
genes known to be translocated in prostate tumors (i.e., ERG,
ETV1 and ETV4) had in fact significantly alterations of other ETS
factors. ESE3 and ESE1 were the most frequently affected ETS
genes. ESE3 and ESE1 are normally expressed in prostate
epithelial cells and their expression was significantly altered ($4-
fold relative to normal prostate) in .40% of cases, including many
tumors with ERG translocation and over-expression. ESE3 and
ESE1 have been shown to act as a tumor suppressor [11] and
oncogene [12], respectively, and thus can have a relevant impact
on prostate tumorigenesis. The mechanism of altered expression of
these ETS factors in prostate tumors is unknown at this time.
Epigenetic events and environmental stress (e.g., inflammation)
might be involved, since we showed that ESE3 is epigenetically
silenced in prostate cancer cells [11] and both ESE3 and ESE1
expression can be affected by inflammatory stimuli [33].
To decipher the network of genes controlled by the aberrantly
expressed ETS factors we divided prostate tumors in groups on the
basis of their ETS expression profile. This approach has been
applied in previous studies [27,34]. The major difference in our
work is that we took in consideration all the ETS genes that had
shown relevant changes in expression and divided tumors
according to their ETS expression status evaluated by real time
PCR instead of relying only on microarray data. Using stringent
criteria we defined four major prostate tumors subgroups.
Principal components and functional annotation analyses indicat-
ed that the tumor subgroups exhibited distinct transcriptional and
biological features. Among the subgroups, ERG
high and ESE3
low
tumors had the most robust transcriptional signatures with many
distinctive features compared to normal prostate and NoETS
tumors. Functional annotation analysis pointed to a strong impact
of these dysregulated ETS factors on the prostate cancer
transcriptome with specific enrichment of genes linked to cell
adhesion, invasion and migration, which might confer a more
aggressive phenotype to these tumors. ETS factors have been
reported to play an important role in extra-cellular matrix
remodeling and epithelial-to-mesenchymal transition and their
over-expression has been linked to increased motility, invasion and
metastasis in various cancer models [35,36]. Notably, the
functional annotation analysis indicated that similar consequences
on the cancer transcriptome derived from the over-expression of
ERG and loss of ESE3 and that these two ETS factors probably
could act in part through common molecular pathways.
Functional assays supported this hypothesis as ERG gain and
ESE3 loss affected similarly cell properties like cell migration and
survival in anchorage-independent conditions.
One of the aims of the study was to identify key genes that could
mediate effects of the dysregulated ETS factors. We focused on
EZH2 that was exclusively up-regulated in ERG
high and ESE3
low
tumors compared to normal prostate and significantly correlated
and anticorrelated with ERG and ESE3, respectively. EZH2 is a
key element of the Polycomb Repressive Complex 2 (PRC2) and is
responsible for the establishment of the repressive H3K27
methylation mark [17,18]. EZH2 is up-regulated in many cancers,
including clinically localized and metastatic prostate cancers
[19,37]. However, the molecular mechanisms by which EZH2
contributes to prostate cancer initiation and progression as well as
the factors controlling its expression in this context remain largely
unknown. Recent studies have shown that EZH2 is a transcrip-
tional target of pRB-E2F, while microRNA miR-26a and miR-101
control it post-transcriptionally [20,21,22,23]. Here, we show that
ERG and ESE3 reciprocally control EZH2. To support our
findings, we performed experiments in prostate cell lines in which
we experimentally modulated ERG expression. Both up- and
down-regulation of ERG affected the expression of EZH2 in the
predicted way. Furthermore, ChIP showed binding of ERG to the
EZH2 promoter, suggesting that ERG could direct transcription of
EZH2. EZH2 promoter occupancy by ERG was also demon-
strated in prostate cancer clinical samples, providing in vivo
evidence of this interaction. Interestingly, we found that ESE3
controlled EZH2 level in the opposite direction. We observed that
there was an inverse relation between ESE3 and EZH2 expression
in prostate tumors. Experiments carried out in stable ESE3knock-
down cells confirmed that ESE3 negatively regulated EZH2.
Intriguingly, ChIP showed that ESE3 was able to bind to the
EZH2 promoter, suggesting that it could act as a transcriptional
Figure 7. Effects of deregulated expression of ERG and ESE3 in prostate cancer cells. A. ERG over-expression and ESE3 knock-down (B)
enhance cell migration. Cells were grown until confluence and starved for 24 h when a scratch was performed on the monolayer. Pictures were taken
at 0 and 72 h. Representative photographs of triplicate experiments are shown. C. Control and ERG over-expressing LNCaP cell clones were plated in
polyhema coated 96-well plates and cell viability was measured using a colorimetric assay at the indicated time points. D. Control and ESE3 knock-
down LNCaP cells were plated in polyhema and assayed as described above. E. VCaP cells were transfected with siRNAs against ERG or EZH2 and
plated in polyhema after 24 h. Cell viability was measured as described above. F. Parental and ERG-expressing (ERG-18) LNCaP cells were transfected
with siRNAs against EZH2 and assayed as indicated above. G. Parental and ERG-expressing (ERG-18) LNCaP cells were transfected with full length
Nkx3.1 expression vector and assayed as indicated above. H. Parental (sh-) and ESE3 knock-down (sh-7) LNCaP cells were transfected with full length
Nkx3.1 expression vector and assayed as indicated above. Data are presented as mean 6 SD of triplicate experiments. *, p,0.01; **, p,0.001.
doi:10.1371/journal.pone.0010547.g007
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in ERG expressing cells, indicating that a direct competition for
EZH2 promoter occupancy might explain the reciprocal regula-
tion of EZH2 by these two ETS factors.
EZH2 is a key factor in the execution of development and
differentiation programs as well as in maintenance of pluripotency
and self-renewal of stem cells [38,39]. Thus, induction of EZH2 by
ETS factors could have important biological consequences and
contribute to altered developmental programs and neoplastic
transformation of prostate epithelial cells. EZH2 has been shown
to control also genes involved cell adhesion, invasion and
migration [40,41], pathways that we found highly enriched in
ERG
high and ESE3
low tumors by functional annotation analysis.
The transcriptomes of both ERG
high and ESE3
low tumors were
characterized by a large number of down-regulated genes. This
‘‘repressive’’ gene signature could be attributed to the dysregulated
activation of epigenetic effectors like EZH2 by ETS factors leading
to silencing of genes with potential anti-tumor activity [37]. We
show that dysregulated expression of ERG and ESE3 was
associated with reduced expression of the Nkx3.1 tumor
suppressor gene. Nkx3.1 is a prostate-specific homeobox protein
involved in prostate development and differentiation and is one of
the earliest markers of prostate epithelial cell differentiation [25].
Nkx3.1 acts as a prostate-specific tumor suppressor and its loss has
an important role in tumor initiation and progression to invasive
disease [25]. This transcription factor integrates multiple signaling
pathways including PTEN/PI3K/AKT, p53 and AR, which all
play critical roles in prostate development and tumorigenesis
[25,42]. Thus, the concomitant induction of EZH2 and attenu-
ation of Nkx3.1 can explain the activation of a broad
dedifferentiation program observed in the transcriptome of
ERG
high and ESE3
low tumors. Re-expression of Nkx3.1 in PC3
cells, in which the gene is silenced, inhibited cell proliferation and
invasion [43]. In contrast, loss of Nkx3.1 has been associated with
transformation and activation oncogenic pathways [44]. We have
observed that re-expression of Nkx3.1 in ERG and ESE3 cell
models significantly reduces survival in anoikis indicating that
Nkx3.1 attenuation mediates at least in part the transforming
effects of ERG gain and ESE3 loss. Several mechanisms have been
shown to contribute to the loss of Nkx3.1 in prostate cancers
including allelic loss, methylation and post-transcriptional control
[26,28]. Here we described an additional pathway leading to its
silencing. We show that Nkx3.1 is directly controlled by ERG and
ESE3 in prostate tumors and EZH2 contributes to its silencing.
ERG bound to the Nkx3.1 promoter and binding was associated
with transcriptional repression as shown also by promoter reporter
assay. Moreover, the Nkx3.1 promoter acquired the repressive
histone H3K27 methylation mark in an ERG-dependent manner
and expression of Nkx3.1 increased upon EZH2 knock-down,
indicating that EZH2 had an important role in Nkx3.1 silencing in
stably ERG expressing cells. On the other hand, we show that
Nkx3.1 expression was activated by ESE3 and that stable knock-
down of ESE3 significantly reduced the expression of Nkx3.1.
Thus, ESE3 influenced the expression of Nkx3.1 by binding to the
gene promoter and acting as a transcriptional activator. At the
same time, ESE3 could prevent Nkx3.1 silencing by repressing
EZH2 and blocking H3K27 methylation. Interestingly, silencing
of Nkx3.1 upon ERG over-expression and ESE3 down-regulation
occurred independently of CpG promoter methylation, consistent
with a major role of EZH2 and H3K27 methylation. Moreover,
while Nkx3.1 expression was controlled positively by ESE3, ERG
abolished this effect by competing with ESE3 for Nkx3.1 promoter
occupancy and increasing EZH2 expression. Thus, these findings
provide a mechanistic explanation for the attenuation of Nkx3.1
expression in ERG
high and ESE3
low tumors and suggest that this
might be a general mechanism to repress tumor suppressor genes
by aberrantly expressed ETS factors. To date, Polycomb
responsive elements have not been defined in mammalian gene
cells. It has been suggested that transcription factors may
contribute to the recruitments of EZH2 on target genes and that
this phenomenon is context dependent [31]. Consistently with this
hypothesis, our data suggest that deregulated expression of ERG
and ESE3 may affect EZH2 recruitment and H3K27 methylation
of target gene promoters. Future studies will be necessary to
determine whether and how ETS factors might direct EZH2 to
selected gene promoters.
Collectively, this work provides novel insights into the complex
role of ETS factors in prostate development and tumorigenesis.
Our findings support the model of an ETS transcriptional network
whose balance regulates the expression of key genes involved in
prostate epithelial cell development and differentiation and whose
disruption can lead to tumorigenesis (Fig. 8). We show that the
epithelial-specific ETS factor ESE3 promotes the expression of
tissue-specific differentiation genes like Nkx3.1 in prostate
epithelial cells, while it represses genes with transforming potential
like EZH2. Furthermore, an oncogenic ETS factor, like ERG,
binds to the promoter of EZH2 and Nkx3.1 and competes with
ESE3 for promoter occupancy reversing its effects. Thus, ESE3
Figure 8. Model of the reciprocal regulation of EZH2 and Nkx3.1 by competing ETS factors. ESE3 controls expression of EZH2 and Nkx3.1
in normal prostate epithelial cells. ERG over-expression or loss of ESE3 leads to abnormal expression of these key genes and promotes cell
transformation.
doi:10.1371/journal.pone.0010547.g008
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competing stimuli and allow the correct developmental and
differentiation programs to proceed. Genetic events or patholog-
ical conditions, such as gene rearrangements [3] or chronic
inflammation [1], could shift the equilibrium in favor of oncogenic
ETS, like ERG and ESE1, and promote the activation of pro-
mitogenic, pro-survival and dedifferentiation programs. In this
context, it is possible that altered expression of ETS factors, like
ESE3 and ESE1, which are normally present in prostate epithelial
cells, might represent an early event, cooperating with or even
preceding ETS gene rearrangements in the early stages of prostate
tumorigenesis.
Materials and Methods
Clinical Sample Collection
Tissue samples and clinical data were collected with the
approval of the Ethics Committee of the Piedmont Region, Italy,
and patients’ written informed consent. Tumor samples (n=65)
were taken from patients undergone to radical prostatectomy.
Normal prostate tissue (n=14) was taken from adult male who
underwent multiple diagnostic prostate biopsies and found to be
disease-free [11]. Age ranges of individuals with cancer and
normal prostate were 50–74 and 48–78 years, respectively.
Clinical parameters such as Gleason, tumor stage, and PSA values
were recorded at the time of surgery. Association between clinical
variables and tumor classification according to ETS expression
status was tested with Fisher test available within R statistical
package.
Microarray Analysis
RNA extracted from tissue samples was amplified and labeled
using Ambion Message Amp I and hybridized on Agilent Human
1A glass arrays using a dye-swap replication scheme as described
[11]. Arrays were scanned with the Agilent B scanner and raw
data files were loaded into the Resolver SE System (Rosetta
Biosoftware) for data normalization and processing applying the
Agilent platform-specific error model. A commercial pool of RNA
from organ donor healthy prostates (Becton Dickinson) was used
as common reference. A log2 gene expression matrix was created
after combining dye-swap replicates. Expression data were filtered
for SD.0.5 across the samples, resulting in 5142 probes.
Microarray data are MIAME compliant and have been deposited
in the Gene Expression Omnibus (GEO accession no. GSE14206).
Quantitative Real-Time PCR
RNA was reverse-transcribed and real-time PCR was per-
formed using custom made primers and SYBR Green chemistry
for ESE3 [11] and commercial primer sets for ERG, ESE1, ETS2,
ETS1, ESE2 and PDEF (Applied Biosystems) on a ABI 7000
system. Samples were analyzed in triplicate. The level of each gene
was calculated by comparing the Ct value in the samples to a
standard curve generated from serially diluted cDNA from a
reference sample and normalizing it to the amount of b-actin as
previously described [11].
Identification of Tumor Subgroups
Tumors were grouped according to the predominantly
expressed ETS factor based on QRT-PCR data and considering
a cut-off of $4 fold change compared to the average value in
normal prostates. Applying this cut-off, up to 80% of tumors had
highly deregulated expression of at least one ETS gene and were
divided into four major subgroups: ERG
high (n=14), ESE1
high
(n=12), ESE3
low (n=13) and NoETS (n=14) tumors. Eight
tumors with high level either of ETV1, ETV4, ETS2 or ETS1
were excluded from the analysis because they did not fit in any of
the other categories and were too heterogeneous to be analyzed
separately. Microarray data from an independent study [14] were
downloaded from the GEO public repository (GSE6956). This set
contained 69 prostate cancers profiled using the Affymentrix
GeneChip HG-U133A 2.0 arrays. Raw Affymetrix CELL files
were processed applying the robust multi-array average (RMA)
procedure within the Affy R package. Expression log intensities of
ERG, ESE3, ESE1, ESE2, ETS2, ETS1 and PDEF were recorded
and samples were classified as ERG
high, ESE3
low, and ESE1
high,
when the level of these genes was at least 3 fold higher or lower
than level observed in NoETS samples.
Principal component analysis
Principal component analysis was performed on the matrix the
5142 filtered genes with highest standard deviation using MeV
version 4.2 (http://www.tm4.org/mev.html). Points representing
individual tumors and normal samples were plotted in a 2D scatter
plot where the coordinates correspond to the first two principal
components (combinations of genes).
Differential Gene Expression and Functional Annotation
Analysis
Differential gene expression analysis between sample classes was
performed on the matrix containing the 5142 filtered genes using
Gene Expression Profile Analysis Suite (GEPAS). Differentially
expressed genes were obtained after filtering for q value (Q #0.1).
To test the difference in gene set overlap, we crossed the lists of up-
regulated and down-regulated genes of each class using a standard
Venn diagram generator. To test the statistical significance of the
differences in shared and distinctive features, we built for each
class pair contingency tables containing observed and expected
overlap and applied the Fisher Exact test. To define the pathways
affected in tumor subgroups the lists of differentially expressed
genes obtained with GEPAS for each tumor subgroup compared
to normal prostate were uploaded into the GeneGO’s Metacore
server (http://portal.genego.com). The Metacore software for
integrated functional analysis of gene expression data compare
distinct datasets to determine biological features shared or unique
to each set. The matrix combining the results from the four class
comparisons (genes with q value #0.1 in at least one class) was
analyzed using the Metacore ‘‘Compare Experiments Workflow’’
tool to visualize enriched features in GeneGo pathway maps
(GGPM). To identify genes correlated and anti-correlated with
ERG and ESE3 we used the R function cor.test( ), which provides
Pearson’s correlation measure along with a P value estimate.
Cell Cultures, Cell Transfection and Selection of Stable
Cell Clones
VCaP, LNCaP, 22Rv1 and PC3 were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA) and
maintained in DMEM (VCaP) or RPMI-1640 (all others)
supplemented with 10% fetal bovine serum. VCaP cells are
ERG translocation positive, AR-positive and androgen dependent
[2]. LNCaP cells are AR-positive, androgen-dependent and carry
the ETV1 gene translocation [4]. 22Rv1 cells are ETS-
translocation negative, AR-positive and androgen-independent
[45]. Immortalized prostate epithelial LHS cells, which have been
engineered to express hTERT and SV40 large T antigen [32],
were maintained in PrEC growth medium (PrEGM, Cambrex,
Lonza Group Ltd, Basel, Switzerland). ERG expressing stable cell
lines were generated by transfection of the pECFL-ha-ERG3
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2000 (Invitrogen) and selection with G418. Negative control cells
were obtained by transfection with pcDNA3.1 and selection in
G418. To establish stable ESE3 knock-down cell lines, cells were
transfected with ESE3 targeting shRNAs (Cat. no. KH14264N
SuperArray, Frederick, MD, USA) using Lipofectamine 2000 and
selected with G418. Negative control cells were generated by
transfection of a control shRNA (SuperArray) with no sequence
homology within the human genome. In both cases, G418
resistant colonies were expanded and expression of ERG and
ESE3 was determined by RT-PCR and Western blotting. Nkx3.1
and EZH2 expression vectors were provided by E. P. Gelmann
and J-T. Hsieh, respectively. For transient gene knock-down cells
were transfected with siRNAs directed to ERG (Cat. no.
Hs_ERG_8, Qiagen, Hilden, Germany), EZH2 (Cat. no. D-
004218-01-0005, Dharmacon, Lafayette, CO, USA) or a control
siRNA directed to the firefly luciferase gene (siGL3, Ambion [46]).
Cells were plated in six-well plates and transfected with 50 nM of
siRNA using Interferin (Polyplus-transfection SA, Illkirch, France)
and were harvested after 72 h.
Luciferase Promoter Reporter assay
Cells were plated in 48-well plates and 24 h later transfected
with the pGL3-Nkx3.1 promoter reporter (provided by J. M.
Bentel) or pGL3-control vector (Promega AG, Wallisellen,
Switzerland) along with control empty vector or ESE-3, ERG,
EZH2 expression vectors. pRL-SV40 (Promega) was used as
control to monitor transfection efficiency. Luciferase activity was
measured after 24 h using the Dual-Luciferase Reporter Assay
System (Promega) as previously described [11]. Data are presented
as percentage of Firefly luciferase activity normalized to the
Renilla luciferase activity relative to cells transfected with control
vector alone. Reporter assays were performed in triplicate and
repeated in three independent experiments.
Anoikis and Migration Assay
Cell viability in anchorage-independent conditions (anoikis
assay) was assessed by plating cells (1610
5cells/well) in poly-hema
coated 96-well plates. Cell viability was measured using a
colorimetric assay (MTT, Sigma) and reading absorbance at
540 nm in a microplate reader. All assays were done in triplicates
and in three independent experiments. Cell migration was assessed
using the scratch wound healing assay [47]. Cells were grown to
confluence in six-well plates and then overnight in serum-free
medium. After scratches were performed on the cell monolayer,
complete medium was added to the cultures and images were
taken at 24–72 h with a Zeiss microscope. The assays were done in
triplicate in three independent experiments.
RT-PCR and Western Blotting
RNA was extracted and end-point RT-PCR was performed
using the SuperScript One-step RT-PCR system (Invitrogen) as
described previously [11]. PCR primers are shown in Table S4.
PCR products were separated by gel electrophoresis and visualized
on a AlphaImager 3400 (AlphaInnotech, Fremont, CA, USA). For
Western blotting, cell lysate preparation, gel electrophoresis and
blotting were performed as described previously [11] using
antibodies for ERG (sc-353, Santa Cruz Biotechnology Inc.,
Heidelberg, Germany), ESE-3 (ETS3 Clone 5A5, Lab Vision,
Fremont CA. USA), EZH2 (612667 BD Biosciences, San Jose,
USA), Nkx3.1 (SC-15022,Santa Cruz Biotechnology Inc.) and a-
tubulin (CP06, Calbiochem). To detect the TMPRSS2:ERGa
fusion transcript, total RNA from tumor (n=53) and normal
prostate tissue (n=14) was reverse-transcribed using random
hexamers and the cDNA amplified with primers located in exon 1
of TMPRSS2 and exon 4 of ERG (Table S4) and Amplitaq Gold
(Applied Biosystems). The TMPRSS2-ERGa specific PCR
product was 184 bp long.
Chromatin Immunoprecipitation (ChIP)
Cells were exposed to formaldehyde to cross-link protein-DNA
complexes and processed as previously described [11,46].
Immuno-precipitation was done with antibodies for ERG (sc-
354 X, Santa Cruz Biotechnology Inc., Heidelberg, Germany),
ESE-3 (ETS3 Clone 5A5, Lab Vision, Fremont, CA USA)[11],
and methylated H3K27 (07-449 Millipore Upstate Biotechnol-
ogy, NY, USA)[6,46]. End-point PCR was performed as
previously described [11,46] using primers spanning the EBS
in the region of interest (shown in Table S4) and Taq Gold
(Roche). PCR products were analyzed by gel electrophoresis.
Quantitative real-time PCR (qPCR) was performed using SYBR
Green qPCR and the primers indicated in Table S4. The
amount of immunoprecipitated DNA was calculated in reference
to a standard curve and normalized to input DNA [46]. To
perform ChIP in clinical samples, fresh frozen tumor specimens
were cut into small pieces, placed in PBS/Na-butyrate/
formaldehyde fixative and then immediately processed for ChIP
as described above. All experiments in cell lines and tumor
specimens were repeated at least three times and representative
results are shown.
Bisulphite Sequencing
Genomic DNA was extracted and bisulphite conversion was
performed using the DNeasy Blood and Tissue kit and the Epitect
Bisulphite kit (Qiagen AG, Hombrechtikon, CH) as described
[11]. Bisulfite-modified DNA was amplified by PCR with primers
and sequenced. Primers for bisulphite sequencing PCR are shown
in Table S4. The location of the CpG island in the Nkx3.1 locus
was determined using the NCBI Map Viewer and the CpG island
map option. Primers for bisulphite sequencing PCR were designed
using Methprimer to interrogate the greatest number of CpG sites
within a single PCR product. PCR products were purified using
the JetQuick PCR purification system (Chemie Brunschwig) and
sequenced on an ABI 3730xl DNA Analyzer.
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independent microarray dataset. (A) Expression of ERG, ESE1
and ESE3 in prostate tumors according to microarray data. (B)
Patient distribution among the four subgroups. (C) ERG level in
NoETS and ERGhigh tumors. (D) ESE3 expression level in
NoETS and ESE3low tumors.
Found at: doi:10.1371/journal.pone.0010547.s006 (0.13 MB
PDF)
Figure S3 TMPRSS2:ERG fusion transcripts in the ERGhigh
tumor, normal prostate and benign prostatic hyperplasia samples
(A). Patient distribution in the four tumor subgroups according to
Gleason score, tumor stage and pre-operatory PSA level (B).
Found at: doi:10.1371/journal.pone.0010547.s007 (0.17 MB
PDF)
Figure S4 Four-way Venn diagrams showing shared and distinct
differentially expressed genes among the four tumor subgroups.
Found at: doi:10.1371/journal.pone.0010547.s008 (0.06 MB
PDF)
Figure S5 Establishment of cell models for ERG and ESE3
target gene identification. (A) Stable clones of ERG transfected
LNCaP and 22Rv1 cells. (B) ERG knock-down in VCaP cells. (C)
ERG target genes in ERG expressing 22Rv1 and LNCaP cells. (D)
ERG target genes in ERG-knock-down VCaP cells. (E) Stable
ESE3 knock-down LNCaP and LHS cells.
Found at: doi:10.1371/journal.pone.0010547.s009 (0.23 MB
PDF)
Figure S6 Positive control experiments for ChIP assays in
VCaP, parental and ERG expressing LNCaP and 22Rv1 cells.
Found at: doi:10.1371/journal.pone.0010547.s010 (0.07 MB
PDF)
Figure S7 Negative control experiments for ChIP assays in ERG
expressing and non-expressing cell lines and in ERGhigh and
NoETS tumors.
Found at: doi:10.1371/journal.pone.0010547.s011 (0.04 MB
PDF)
Figure S8 Negative control experiments for ChIP assays in
parental and ERG-expressing LNCaP cells and parental and ESE-
kd LNCaP cells.
Found at: doi:10.1371/journal.pone.0010547.s012 (0.04 MB
PDF)
Figure S9 Negative control experiments for ChIP assays in
parental and ESE-kd LNCaP cells and parental and ERG-
expressing LNCaP cells.
Found at: doi:10.1371/journal.pone.0010547.s013 (0.04 MB
PDF)
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